肠道超声用于监测克罗恩病活动性的多中心前瞻性研究
这项在德国47个中心开展的前瞻性非干预研究纳入234例处于活动期的成年克罗恩病患者,在基线及第3、6、12个月评估超声参数与临床数据。结果显示第3和12个月时几乎所有超声参数均显著改善(P<.01),肠壁厚度改善与第3个月C反应蛋白下降相关(P≤.001),中位Harvey-Bradshaw指数从基线10降至12个月后2。
要点
- 肠道超声可监测活动期克罗恩病患者的疾病活动性。
- 第3和12个月时几乎所有超声参数显著改善,P<.01。
- 肠壁厚度改善与第3个月C反应蛋白下降相关,P≤.001。
核心结论
- 多中心前瞻性研究显示,超声检查可用于监测活动期克罗恩病患者的疾病活动性。
- 肠道超声似乎是评估药物治疗后疾病活动性早期透壁变化的理想随访方法。
研究设计与样本
- 在德国47个中心开展为期12个月的前瞻性非干预研究,时间为2010年12月至2014年9月。
- 纳入234例经历疾病发作(Harvey-Bradshaw指数评分≥7)的成年克罗恩病患者。
- 所有患者均接受治疗强化,大多数使用肿瘤坏死因子拮抗剂。
- 在基线及第3、6、12个月评估超声参数和临床数据,主要终点为入组12个月内超声参数的变化。
主要发现
- 所有入组患者均存在回肠末端和/或结肠节段的肠壁改变。
- 第3和12个月时超声检查显示几乎所有超声参数显著改善,包括肠壁增厚或分层减少、纤维脂肪增生减少及彩色多普勒超声信号增加(第3和12个月所有参数P<.01)。
- 中位Harvey-Bradshaw指数评分从基线10降至12个月后2。
- 肠壁厚度改善与第3个月C反应蛋白水平降低相关(P≤.001)。
临床怎么用
- 作者认为,肠道超声似乎是评估药物治疗后疾病活动性早期透壁变化的理想随访方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: We performed a multicenter study to determine whether transabdominal bowel wall ultrasonography, a noninvasive procedure that does not require radiation, can be used to monitor progression of Crohn's disease (CD). METHODS: We performed a 12-month prospective, noninterventional study at 47 sites in Germany, from December 2010 through September 2014. Our study included 234 adult patients with CD who experienced a flare, defined as Harvey-Bradshaw index score of ≥7. All patients received treatment intensification, most with tumor necrosis factor antagonists. Ultrasound parameters and clinical data were assessed at baseline and then after 3, 6, and 12 months. The primary endpoint was the change in ultrasound parameters within 12 months of study enrollment. RESULTS: All patients included had bowel wall alterations either within the terminal ileum and/or segments of the colon. After 3 and 12 months, ultrasonographic examination showed significant improvements of nearly all ultrasound parameters, including reductions in bowel wall thickening or stratification, decreased fibrofatty proliferation, and increased signals in color Doppler ultrasound (P < .01 for all parameters at months 3 and 12). Median Harvey-Bradshaw index scores decreased from 10 at baseline to 2 after 12 months. Improvement in bowel wall thickness correlated with reduced levels of C-reactive protein after 3 months (P ≤ .001). CONCLUSIONS: In a multicenter prospective study, we found that ultrasonographic examination can be used to monitor disease activity in patients with active CD. Bowel ultrasonography seems to be an ideal follow-up method to evaluate early transmural changes in disease activity, in response to medical treatment. German Clinical Trials Register: drks.de/DRKS00010805.
引用
- Kucharzik T, Wittig BM, Helwig U, et al. Use of Intestinal Ultrasound to Monitor Crohn's Disease Activity. Clin Gastroenterol Hepatol. 2016. PMID: 27856365. doi:10.1016/j.cgh.2016.10.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。